These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30359558)

  • 1. Revised Australian national guidelines for colorectal cancer screening: family history.
    Jenkins MA; Ait Ouakrim D; Boussioutas A; Hopper JL; Ee HC; Emery JD; Macrae FA; Chetcuti A; Wuellner L; St John DJB
    Med J Aust; 2018 Nov; 209(10):455-460. PubMed ID: 30359558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
    Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
    BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
    Ladabaum U; Mannalithara A; Mitani A; Desai M
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline.
    Helsingen LM; Vandvik PO; Jodal HC; Agoritsas T; Lytvyn L; Anderson JC; Auer R; Murphy SB; Almadi MA; Corley DA; Quinlan C; Fuchs JM; McKinnon A; Qaseem A; Heen AF; Siemieniuk RAC; Kalager M; Usher-Smith JA; Lansdorp-Vogelaar I; Bretthauer M; Guyatt G
    BMJ; 2019 Oct; 367():l5515. PubMed ID: 31578196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
    Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
    BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk.
    Sroczynski G; Hallsson LR; Mühlberger N; Jahn B; Rehms R; Hoffmann S; Crispin A; Lindoerfer D; Mansmann U; Siebert U
    Int J Cancer; 2024 Feb; 154(3):516-529. PubMed ID: 37795630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bowel cancer screening for women at midlife.
    Olver I
    Climacteric; 2018 Jun; 21(3):243-248. PubMed ID: 29609509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
    Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
    Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review.
    Tanadi C; Tandarto K; Stella MM; Sutanto KW; Steffanus M; Tenggara R; Bestari MB
    Rom J Intern Med; 2024 Jun; 62(2):101-123. PubMed ID: 38153878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations on prevention and screening for colorectal cancer in Hong Kong.
    Lam TH; Wong KH; Chan KK; Chan MC; Chao DV; Cheung AN; Fan CY; Ho J; Hui EP; Lam KO; Law CK; Law WL; Loong HH; Ngan RK; Tsang TH; Wong MC; Yeung RM; Ying AC; Ching R
    Hong Kong Med J; 2018 Oct; 24(5):521-526. PubMed ID: 30318477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
    Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.